BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved ...
(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. Food and Drug Administration has approved its iohexol injection (300 mg Iodine/mL), the first generic version of GE Healthcare's ...
Hosted on MSN
Amneal gets FDA nod for Iohexol Injection
Amneal Pharmaceuticals (AMRX) has received approval from the U.S. FDA for its iohexol injection, which contains 300 mg of iodine per mL. This marks the introduction of the first generic version of GE ...
Amneal Pharmaceuticals received approval from the Food and Drug Administration for its generic iohexol injectable. The company said Thursday it expects to launch the iodine-based medication, which is ...
BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced Thursday that the U.S. Food and Drug Administration has approved its iohexol injection (300 mg Iodine/mL), the first generic ...
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented positive results today from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN ...
(MENAFN- GlobeNewsWire - Nasdaq) First-to-market complex injectable with expected launch in Q1 2026 BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or ...
BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (Nasdaq: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback